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Methods. The Agent Working Group evaluated the need to develop new surveillance systems for
quantifying ingredients and emissions of tobacco and tobacco smoke and to improve methods to assess
uptake and metabolism of these constituents taking into account variability in human smoking behavior.
Results. The toxic properties of numerous tobacco and tobacco smoke constituents are well known, yet
systematic monitoring of tobacco products has historically been limited to tar, nicotine, and CO in
mainstream cigarette smoke using a machine-smoking protocol that does not reflect human smokingper (II of V on monitoring the tobacco use epidemic) summarizes the findings
he Agent (product) Working Group of the November, 2002, National Tobacco
behavior. Toxicity of smokeless tobacco products has not been regularly monitored. Tobacco products are
constantly changing and untested products are introduced into the marketplace with great frequency,
including potential reduced-exposure products (PREPs). The public health impact of new or modified tobacco
products is unknown.
Conclusions. Systematic surveillance is recommended for mainstream smoke constituents such as
polycyclic aromatic hydrocarbons (PAH), tobacco-specific nitrosamines (TSNA), total and free-base nicotine,
volatile organic compounds, aromatic amines, and metals; and design attributes including tobacco blend,
additives, and filter ventilation. Research on smoking topography is recommended to help define machine-
smoking protocols for monitoring emissions reflective of human smoking behavior. Recommendations are
made for marketplace product sampling and for population monitoring of smoking topography, emissions of
toxic constituents, biomarkers of exposure and, eventually, risk of tobacco-related diseases.
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Despite longstanding knowledge of the toxicity and carcinogeni-
city of many of the thousands of constituents of tobacco and tobacco
smoke, systematic monitoring has been historically limited to only
three: tar, nicotine, and carbon monoxide in mainstream smoke.
Table 1
Short- and long-term recommendations of the Agent Working Group for research and
implementation of tobacco constituent surveillance
Short-term recommendations
(within 12- to 24-months)
Long-term recommendations
(within 5 years)
#1: Begin surveillance of content
and composition of unburned or
non-combustible tobacco
products; support research to
identify toxicological assays for
subsequent use in monitoring.
#1: Establish a surveillance system of
mainstream cigarette smoke composition
based upon analytes listed in Table 2
#2: Develop topography-based
machine-smoking protocols
#2: Support research to determine a core
set of human biomarkers and begin
surveillance of the most relevant
biomarkers (see Table 2)
S12 S.D. Stellman, M.V. Djordjevic / Preventive Medicine 48 (2009) S11–S15(Stratton et al., 2001) Even this limited effort is inadequate, as it is
based upon a machine-smoking protocol that does not reflect human
smoking topography and its variability (Djordjevic et al., 2000).
Furthermore, ingredients of smokeless tobacco products have never
been monitored. Manufactured cigarettes and other tobacco products
are constantly changing and new products are constantly introduced,
including potential reduced-exposure products (PREPs). The public
health impact of new or substantially altered tobacco products is
unknown (Stratton et al., 2001; National Cancer Institute, 2001;
Hatsukami et al., 2006; Pankow et al., 2007).
The Agent (product) Working Group of the National Tobacco
Monitoring Research and Evaluation Workshop focused on monitor-
ing toxic smoke constituents of cigarettes and the composition of
cigarettes and other tobacco products with emphasis on the need to
provide measurements which (a) reflect a wide range of toxic
compounds relevant to human health, and (b) do so in a manner
which reflects human use behavior.
The selection of specific compounds for monitoring is not a simple
process. Chemical compounds found in the mainstream smoke of
cigarettes number well into the thousands (Hecht and Samet, 2007;
IARC, 2004) and belong to a variety of chemical families with distinct
toxic, carcinogenic, physiological, and metabolic properties. Even
assuming that a reasonable choice of analytes can be made, the
measurement procedure itself is a matter of considerable current
debate centering on the choice of a protocol for machine-smoking
cigarettes. It was the conclusion of the Agent Working Group that no
existing protocol could as yet provide a framework for comprehensive
product surveillance, and consequently that a program of research in
this direction would be an important recommendation, as described
below. The Agent Working Group's recommendations are consistent
with a set of tobacco product research and testing guidelines which
were approved and adopted by the WHO Study Group on Tobacco
Product Regulation (TobReg) in Montebello, Canada, in 2004 (WHO
Study Group on Tobacco Product Regulation, 2004).
Methods
Existing surveillance and monitoring methods
The Working Group's starting point was an assessment of current
monitoring activity, which is driven to a large extent by legal
requirements imposed by the US Federal Trade Commission (FTC).
Since 1967 the FTC has reported yields of tar, nicotine, and carbon
monoxide in nearly all cigarette brands marketed in the US. Reporting
extends to sub-brand varieties (e.g., hard and soft pack, 85 mm and
100 mm, “lights” and “ultra-lights”) which number about 1300
distinct products (Federal Trade Commission, 2000). Since 1987
these data have been assayed and reported to the FTC by laboratories
operated by the tobacco industry.
The usefulness of FTC report data for public health monitoring is
limited for a number of reasons. First tobacco smoke is a mixture of
thousands of chemicals of which many exhibit toxic effects ranging
from cancer to cardiovascular disease, respiratory effects, and
adverse birth outcomes (IARC, 2004; US Surgeon General, 2004).
The three smoke components currently mandated by the FTC do not
capture the range of potential toxicity qualitatively associated with
cigarette smoking, and therefore cannot provide a rational basis for
quantifying or ranking products and associated risks (Fowles and
Dybing, 2003). Furthermore, although the Agent Working Group
focused on the composition and potential health effects of main-
stream tobacco smoke, it has recently been reported that industry-
sponsored toxicological studies have shown that sidestream smoke
toxicity increases with aging and exposure duration, which may
help explain the relatively large biological effects of sidestream
smoke compared to equivalent amounts of mainstream smoke
(Schick and Glantz, 2006).Secondly, cigarettes are the only tobacco products whose con-
stituents have been routinely monitored. It was established decades
ago that use of snuff and chewing tobacco increases the risk of cancer
of the mouth and other organs (National Cancer Institute, 1992;
Cogliano et al., 2004) and it has been amply documented that
smokeless tobacco contains a wide variety of carcinogenic nitrosa-
mines (Djordjevic et al., 1989; Hoffmann et al., 1991, 1995).
Third, cigarette yields as reported by the FTC are measured using a
tobacco industry testing protocol based on machine-smoking of
cigarettes which does not reflect human exposure. This is well
recognized even within the tobacco industry, which has flatly stated:
“The machine results are not necessarily predictive of yields created
by individual consumers. Smokers not only smoke different brands
differently, but they also smoke the same brand differently depending
upon a host of human, social and environmental variables.” (CORESTA,
2005).
Fourth, the practice of surveillance to date has been limited almost
entirely to the tobacco product itself and has not made routine use of
methods measuring physical human smoking patterns (topography)
(Djordjevic et al., 2000; Hammond et al., 2005), the pharmacology of
nicotine, (Benowitz, 1999) or use of biomarkers (Shields, 2002). It was
the conclusion of the Agent Working Group that a responsible
surveillance program should take these factors into consideration.
Finally, manufactured cigarettes and other tobacco products are
continuously changing and new products are constantly introduced
into the marketplace, such as PREPs. These include products such as
Brown &Williamson's Advance, RJ Reynolds's Eclipse and Camel Snus,
Philip Morris's Accord and Marlboro Ultrasmooth, Vector's Omni and
Quest, and Star Scientific's Ariva. The potential public health impact of
several of these products was evaluated by a group of multi-
disciplinary experts convened by the Institute of Medicine in 1999,
which was charged with addressing “the science base for harm
reduction” (Stratton et al., 2001). Hatsukami et al. recently summar-
ized the IOM recommendations regarding PREPS, noting that such
products accomplish their aims with a variety of techniques, including
addition of catalysts to reduce polycyclic aromatic hydrocarbon (PAH)-
associated carcinogens, use of genetically modified plants to alter
nicotine content and nitrosamine formation, and use of carbon filters
to selectively reduce toxicants (Hatsukami et al., 2005). Pankow et al.
estimated potential lung cancer risk reduction for four PREP
prototypes and four commercial PREP products, and concluded that
switching to these products would not reduce risk by more than 2%
(Pankow et al., 2007).
Attentionwas also drawn by Hatsukami et al. to commercial use of
modified curing methods to reduce nitrosamines (Hatsukami et al.,
2005). For example, tobacco for the Brown & Williamson product
is processed by a curing method, patented by Star Scientific, of
Petersburg, VA, which produces low-nitrosamine tobacco. The
declared corporate mission of Star is “to reduce toxins in tobacco so
that adult consumers can have access to products that expose them to
Table 2
Tobacco smoke constituents proposed as targets of surveillance
Mainstream
smoke component
Reason for inclusion Examples
Nicotine Addicting agent
Tar Carcinogenicity





Uptake facilitation Free-base nicotine, ammonia,
pH (measured using methods
described by Pankow et al.
(Pankow et al., 2003a,b and








































Phenols, catechols Cocarcinogens Phenol, catechol
Free radicals Carcinogen mechanisms
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Working Group was concerned that there is no monitoring system
to test the validity of such claims. The public health impact of rapid
and drastic changes in tobacco products on a population of millions of
smokers is unknown.
Results
The short- and long-term recommendations of the Agent
Working Group are presented in Table 1. As part of its first
recommendation, the Agent Working Group enumerated a set of
tobacco product characteristics that the industry should report on a
regular basis which would alert the public health community and
regulators to potential major shifts in product composition. These
include the composition of tobacco blend (tobacco type, curing
technology, use of reconstituted tobacco sheets and expanded
tobacco), cigarette physical design factors (length, circumference,
filter type, and percent ventilation; paper porosity; tobacco weight
per cigarette), and specific additives. Additionally, this recommen-
dation would cover smokeless products such as moist snuff as well
as emerging PREPs. It would cover recent introductions such as low-
nitrosamine smokeless and spitless tobacco products, for which
limited human risk data are available (Levy et al., 2004).
The second short-term recommendation would lay the ground-
work for a future, more comprehensive monitoring system by creating
and funding a research program to develop machine-smoking
protocols based upon comprehensive assessment of human smoking
topography. There is current scientific consensus that yields of tar,
nicotine and other smoke constituents derived from machine-
smoking using the US Federal Trade Commission (FTC)/International
Standardization Organization (ISO) protocols do not provide valid
estimates of human exposure or of relative human exposure when
smoking different brands of cigarettes (National Cancer Institute,
2001). The limitations of a single machine testing protocol for esti-
mating human exposure are due to both the variation in individual
smoking patterns and to systematic differences in smoking patterns
that result when cigarettes with different designs are smoked. The
difficulty of mimicking human smoking with existing regimens has
been discussed by Hammond and colleagues who reviewed four
alternative machine-smoking regimens of varying puff frequency
and volume, filter blockage, and flow rate (Hammond et al., 2006;
Hammond et al., 2007). The protocols included the “intense” Canadian
method (puff volume=55 ml, puff frequency=30 s, filter block-
age=100%, flow rate=27.5 ml/s). They concluded that none of the
methods tested was more representative of human smoking behavior
than the FTC/ISO method (35 ml, 60 s, 0% blockage, 27.5 ml/s), and
none provided better predictors of human exposure. Machine testing
using protocols currently in use should not be used to support claims
of reduced risk. New protocols would be useful to characterize
cigarette emissions for design and regulatory purposes although
communication of machine measurements to smokers can result in
misinformation about differences in exposure and risk across brands.
Two longer term recommendations also flow from these proposals.
The first is establishment of a program of surveillance of tobacco
smoke components based on human smoking parameters. The Agent
Working Group recognized that considerable preliminary research is
required in order to develop a consensus on the types of instrumenta-
tion needed, specific behavioral measurements, and working proto-
cols, which are implicit in this recommendation.
The second long-term recommendation is that surveillance
include biomarkers of human exposure in body fluids such as saliva,
serum or plasma, and urine (see Table 2). Serum cotinine has long
been used routinely to monitor cigarette smoking patterns (O'Connor
et al., 2006) as well as exposure to secondhand smoke in defined
populations (Pirkle et al., 2006). Other available biomarkers include
thiocyanate, metabolites of tobacco-specific nitrosamines (TSNA),glucuronidation products, PAH adducts with DNA and hemoglobin,
and genetic markers, as reviewed by Shields (2002) and by Hatsukami
et al. (2006). At present, these metabolic products can supplement or
replace relatively crude dosage measures such as number of cigarettes
per day and FTC tar and nicotine yield. However, despite the
widespread and growing use of dosage biomarkers, investigators
vary widely in their choice of biomarkers and a consensus on a specific
set of compounds has not yet emerged. Furthermore, as Hatsukami et
al. pointed out in a recent review, no satisfactory biomarkers are as yet
available which are reliably predictive of tobacco-related diseases
(Hatsukami et al., 2006).
Discussion
Methods, challenges, and opportunities
As noted by Giovino et al. (2009) in their Overview paper, tobacco
usage in our society is a complex public health problem that requires a
variety of coordinated approaches. As described in this paper, The
Agent Working Group focused on the physical, chemical, and
biological properties of tobacco products (Stellman and Djordjevic,
2009). Other Working Groups addressed the need to improve
population survey methods used to track use of tobacco products
(Delnevo and Bauer, 2009), to identify and understand the societal
factors that influence tobacco use by individuals (Farrelly, 2009), and
to monitor the behavior of the tobacco industry as it adapts to
S14 S.D. Stellman, M.V. Djordjevic / Preventive Medicine 48 (2009) S11–S15increasing pressures of social constraints on the marketplace (Cruz,
2009).
The Agent Working Group evaluated the need to develop new
surveillance systems, in light of the foregoing limitations of existing
knowledge and methods for quantifying critical components of
tobacco and tobacco smoke. The evaluation was influenced by
several important considerations. First, surveillance of tobacco
smoke should be expanded to include classes of chemicals that
are found both in particulate matter and the gas/volatile phase, and
that are known to play important roles in human illness.
Furthermore, surveillance should not be based on the misleading
FTC machine-smoking protocol but should take account of the
variety and variability of human smoking behavior. The Agent
Working Group strongly recommended that the practice of
surveillance should be extended beyond tobacco and smoke to
include measurement in humans of metabolites and other biomar-
kers of exposure to tobacco products.
It was recognized that recommendations involving disclosure of
tobacco composition require no new technology and could be
achieved relatively quickly in a regulated environment. On the other
hand, before topography-based surveillance can be implemented,
protocols for assessing human smoking behavior must be developed
which cover a wide range of tobacco products (e.g., cigarettes whose
nicotine yield ranges from very low to high) and must be suitable
for large-scale implementation. Therefore, two short-term recom-
mendations address, respectively, an immediate program of tobacco
product surveillance and a research program to develop topography-
based machine-smoking protocols (Table 1).
Wishing to be as specific as possible the Agent Working Group
drew up a list of candidate tobacco smoke constituents based on their
potential health effects and the availability of appropriate measure-
ment technology (Table 2) (Hecht and Samet, 2007). These include
families of carcinogens such as PAH and nitrosamines, heavy metals,
aromatic amines, and compounds which in addition to toxic effects
may affect the uptake of toxic agents either pharmacologically (e.g.,
ammonia content and smoke pH) (Willems et al., 2006; Pankow,
2001; Pankow et al., 2003a,b; Watson et al., 2004) or via physiological
action as may be the case with menthol (Wayne and Connolly, 2004).
Some research needs regarding measurement of tobacco smoke pH
were previously discussed by Henningfield et al., who noted that
addition of ammonia and ammonia precursor compounds to tobacco
leads to an increase in the amount of nicotine present in both
particulate matter and vapor as the unprotonated free base, which
may affect human uptake of other smoke components (Henningfield
et al., 2004).
Conclusions
The Agent Working Group of the National Tobacco Monitoring,
Research and Evaluation Workshop evaluated the need to develop
new surveillance systems for quantifying ingredients and emissions
of tobacco and tobacco smoke as well as the need to improve
methods to assess uptake and metabolism of these constituents by
tobacco users. Constituents of mainstream smoke recommended for
surveillance included specific PAH and TSNA, total and free-base
nicotine, volatile organic compounds, aromatic amines, and metals.
Cigarette design attributes recommended for monitoring included
tobacco blend, additives, and filter ventilation. We also recom-
mended research to help define machine-smoking protocols for
monitoring emissions reflective of human smoking behavior,
marketplace product sampling, and population monitoring of
smoking topography, emissions of toxic constituents, biomarkers
of exposure and, eventually, risk of tobacco-related diseases.
This research program should be carried out by research groups
who are independent of the tobacco industry, which is unfortu-
nately now the major source of data on tobacco and tobacco smoke.Building such research capacity is an expensive, long-term proposi-
tion. A coordinated effort will require the support of established
health agencies.
It should be noted that while the Agent Working Group was part
of a US-based workshop, recommendations along similar lines have
also been made by international organizations. The World Health
Organization Study Group on Tobacco Product Regulation (TobReg)
has recently published a proposal for mandated lowering of specific
toxicants in cigarette smoke, as developed by a joint working group of
the International Agency for Research on Cancer (IARC) and the WHO
(Burns et al., 2008). The TobReg proposal seeks to impose a ceiling on
each of nine selected mainstream smoke constituents, including
NNK, carbon monoxide, and benzo(a)pyrene. The emissions stan-
dards recommended by the WHO working group are based on a
single machine-smoking regimen, namely, that of Health Canada. No
recommendations were made regarding measurement of biomarkers
of exposure or other indicators of disease risk. The WHO working
group noted that “[r]esearch is needed to resolve these issues [i.e.,
variability of human smoking behavior] in order to allow exposure
biomarkers to become an effective tool for product regulation.”
(Burns et al., 2008) Thus, the recommendations of the present Agent
Working Group go considerably beyond those of TobReg, in that they
prescribe a program of biomarker surveillance and human smoking
behavior research which could eventually provide the scientific basis
for more extensive regulatory proposals.
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